Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR – Get Free Report)’s stock price gapped down prior to trading on Friday. The stock had previously closed at $13.40, but opened at $12.69. Pharming Group shares last traded at $12.5650, with a volume of 1,735 shares changing hands.
Analyst Upgrades and Downgrades
PHAR has been the topic of a number of recent analyst reports. Canaccord Genuity Group boosted their target price on shares of Pharming Group from $38.00 to $41.00 and gave the stock a “buy” rating in a report on Thursday, October 29th. HC Wainwright reiterated a “buy” rating and issued a $37.00 price target on shares of Pharming Group in a research note on Tuesday, September 22nd. Weiss Ratings raised shares of Pharming Group from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday. Oppenheimer reissued an “outperform” rating on shares of Pharming Group in a research report on Wednesday, October 28th. Finally, Wall Street Zen upgraded shares of Pharming Group from a “hold” rating to a “strong-buy” rating in a research note on Sunday, November 1st. Three analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $39.67.
Get Our Latest Research Report on PHAR
Pharming Group Price Performance
The company has a current ratio of 3.23, a quick ratio of 2.65 and a debt-to-equity ratio of 0.32. The company has a 50 day moving average price of $10.96 and a 200 day moving average price of $13.48. The company has a market capitalization of $891.83 million, a P/E ratio of 39.38 and a beta of -0.05.
Pharming Group (NASDAQ:PHAR – Get Free Report) last posted its quarterly earnings results on Tuesday, October 27th. The company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $0.09. Pharming Group had a return on equity of 8.70% and a net margin of 6.23%. The business had revenue of $117.60 million for the quarter, compared to analysts’ expectations of $117.60 million. On average, equities analysts predict that Pharming Group N.V. Sponsored ADR will post 0.34 EPS for the current fiscal year.
Hedge Funds Weigh In On Pharming Group
A hedge fund recently bought a new position in Pharming Group stock. MAC Alpha Capital Management LP bought a new position in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR – Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 2,148,144 shares of the company’s stock, valued at approximately $29,838,000. Pharming Group comprises approximately 6.0% of MAC Alpha Capital Management LP’s holdings, making the stock its 2nd biggest holding. MAC Alpha Capital Management LP owned about 3.03% of Pharming Group as of its most recent SEC filing. Hedge funds and other institutional investors own 0.03% of the company’s stock.
About Pharming Group
Pharming Group N.V. is a biotechnology company headquartered in Leiden, the Netherlands, that develops and commercializes medicines for rare and underserved diseases. Founded in 1988, the company has built its business around treatments for disorders involving the immune system. Its marketed products include Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, and Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS).
Recommended Stories
- Five stocks we like better than Pharming Group
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.
